Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 10/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 7/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | FNTA | P49354 | 4/20 | 0.42 |
| ▸ | FNTB | P49356 | 4/20 | 0.42 |
| ▸ | PGGT1B | P53609 | 4/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28555237 | 0.90 | ACE (0.40) | FNTAFNTBPGGT1B | |
| SCHEMBL30052897 | 0.78 | KMT2A (0.63) | OPRD1OPRM1OPRK1KMT2AFNTA | |
| Water SCHEMBL10955730 | 0.76 | OPRD1 (0.37) | OPRD1OPRM1OPRK1KMT2AFNTA | |
| SCHEMBL30052536 | 0.76 | FNTA (0.55) | OPRD1OPRM1OPRK1KMT2AFNTA | |
| SCHEMBL632433 | 0.75 | OPRD1 (0.62) | OPRD1OPRM1OPRK1KMT2AFNTA | |
| SCHEMBL11397444 | 0.75 | OPRD1 (0.62) | OPRD1OPRM1OPRK1KMT2AFNTA | |
| SCHEMBL29388464 | 0.75 | OPRD1 (0.62) | OPRD1OPRM1OPRK1KMT2AFNTA | |
| SCHEMBL1880497 | 0.75 | OPRD1 (0.62) | OPRD1OPRM1OPRK1KMT2AFNTA | |
| SCHEMBL138411 | 0.75 | OPRD1 (0.62) | OPRD1OPRM1OPRK1KMT2AFNTA | |
| SCHEMBL5812102 | 0.75 | OPRD1 (0.62) | OPRD1OPRM1OPRK1KMT2AFNTA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080260829-A1 | Bone morphogenic proteins (bmp); cell adhesion modulating agent; peptidomimetics of cyclic peptides comprising classical cadherin cell adhesion recognition (CAR) sequences; modulate cell adhesion and improve drug delivery | NEW YORK SOCIETY FOR THE RUPTURED AND CRIPPLED MAINTAINING THE HOSPITAL FOR SPECIAL SURGERY (US) | 2008-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080260829-A1 | Bone morphogenic proteins (bmp); cell adhesion modulating agent; peptidomimetics of cyclic peptides comprising classical cadherin cell adhesion recognition (CAR) sequences; modulate cell adhesion and improve drug delivery | BMP1, BMP2, BMP4 | OPRD1 3228/4885OPRM1 2192/4885OPRK1 3736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.